Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

NCT: NCT04879940 · ACTIVE_NOT_RECRUITING

NCT IDNCT04879940
StatusACTIVE_NOT_RECRUITING
Start Date2022-02-23
Completion2027-02

Brief Summary

This is a Phase II prospective clinical trial in which patients with prostate carcinoma and obstructive lower urinary tract symptoms electing for radiation therapy will undergo Prostatic Artery Embolization (PAE) prior to treatment. PAE will be administered by Interventional Radiology. Patients will be seen for follow-up at 6 weeks and 12 weeks following PAE after which they will start definitive radiotherapy. After completion of radiotherapy the patient will be seen at 12 weeks

Frequently Asked Questions

What is Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization?

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization is a clinical trial registered under NCT04879940. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04879940?

The current status of NCT04879940 (Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization) is: ACTIVE_NOT_RECRUITING.

When did Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization start?

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization started on 2022-02-23.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑